ES2059538T3 - Vectores y compuestos para expresion directa de proteina c humana activada. - Google Patents

Vectores y compuestos para expresion directa de proteina c humana activada.

Info

Publication number
ES2059538T3
ES2059538T3 ES88311421T ES88311421T ES2059538T3 ES 2059538 T3 ES2059538 T3 ES 2059538T3 ES 88311421 T ES88311421 T ES 88311421T ES 88311421 T ES88311421 T ES 88311421T ES 2059538 T3 ES2059538 T3 ES 2059538T3
Authority
ES
Spain
Prior art keywords
vectors
compounds
human protein
direct expression
activated human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88311421T
Other languages
English (en)
Inventor
Nils Ulrik Bang
Hartmut Josef Ehrlich
Brian William Grinnell
Stanley Richard Jaskunas Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2059538T3 publication Critical patent/ES2059538T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE DESCRIBE UN METODO PARA LA PRODUCCION RECOMBINANTE DIRECTA DE PROTEINA C ACTIVADA. TAMBIEN SE INCLUYEN EN LA INVENCION COMPUESTOS DE DNA, VECTORES Y TRANSFORMANTES UTILES EN EL METODO. EL METODO IMPL,ICA LA TRANSFORMACION Y CULTIVO DE UNA CELULA HUESPED CON UN VECTOR DE DNA RECOMBINANTE QUE CODIFICA MOLECULAS DE PROTEINA C EN LAS QUE EL PEPTIDO DE ACTIVACION ESTA REE,PLAZADO POR UNA SECUENCIA DE ESCISION PARA UNA PROTEASA ASOCIADA A LA CELULA.
ES88311421T 1987-12-04 1988-12-02 Vectores y compuestos para expresion directa de proteina c humana activada. Expired - Lifetime ES2059538T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/129,027 US4992373A (en) 1987-12-04 1987-12-04 Vectors and compounds for direct expression of activated human protein C

Publications (1)

Publication Number Publication Date
ES2059538T3 true ES2059538T3 (es) 1994-11-16

Family

ID=22438133

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88311421T Expired - Lifetime ES2059538T3 (es) 1987-12-04 1988-12-02 Vectores y compuestos para expresion directa de proteina c humana activada.

Country Status (20)

Country Link
US (1) US4992373A (es)
EP (1) EP0319312B1 (es)
JP (1) JP2749083B2 (es)
KR (1) KR970009081B1 (es)
CN (1) CN1035527A (es)
AR (1) AR245217A1 (es)
AT (1) ATE96840T1 (es)
AU (1) AU610301B2 (es)
CA (1) CA1339938C (es)
DE (1) DE3885419T2 (es)
DK (1) DK672788A (es)
ES (1) ES2059538T3 (es)
HU (1) HU209587B (es)
IE (1) IE61627B1 (es)
IL (1) IL88559A (es)
MX (1) MX166847B (es)
NZ (1) NZ227177A (es)
PT (1) PT89135B (es)
RU (1) RU1830081C (es)
ZA (1) ZA889033B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6437298A (en) * 1987-08-04 1989-02-07 Hiroshi Okamoto Production of c-terminal amidated peptide
DK0485504T3 (da) * 1989-08-11 1994-04-18 Zymogenetics Inc Fremgangsmåde til fremstilling af aktiveret protein C ved celledyrkning
EP0506821B1 (en) * 1989-12-29 1998-02-04 Zymogenetics, Inc. Hybrid protein c
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
CA2096418C (en) * 1990-11-26 2001-11-20 Philip J. Barr Expression of pace in host cells and methods of use thereof
JPH06507307A (ja) * 1991-01-11 1994-08-25 アメリカン・レツド・クロス トランスジェニック動物の乳腺組織における活性ヒトプロテインｃの発現
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US6262336B1 (en) 1991-01-11 2001-07-17 American Red Cross Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
US5464934A (en) * 1993-05-14 1995-11-07 Mallinckrodt Medical, Inc. Metal chelates as spacer compounds in biologically active peptides
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
US5698444A (en) * 1993-12-23 1997-12-16 Eli Lilly And Company Serotonin receptor protein and related nucleic acid compounds
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US5723755A (en) * 1995-05-16 1998-03-03 Francis E. Lefaivre Large scale production of human or animal proteins using plant bioreactors
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
US5905185A (en) * 1995-11-30 1999-05-18 Ppl Therapeutics Protein C production in non-human transgenic mammals
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
US6159468A (en) * 1997-04-28 2000-12-12 Eli Lilly And Company Activated protein C formulations
KR20010013413A (ko) * 1997-06-05 2001-02-26 피터 지. 스트링거 혈전성 질환의 치료 방법
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6103524A (en) * 1998-07-30 2000-08-15 Eli Lilly And Company Metabotropic glutamate receptor protein and nucleic acid
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
WO2000023101A1 (en) 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
CA2351067A1 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
CN1326356A (zh) 1998-11-20 2001-12-12 伊莱利利公司 治疗病毒性出血热的方法
AU1723200A (en) 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
US6420157B1 (en) * 1999-04-30 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Zymogen activation system
CA2372907A1 (en) * 1999-04-30 2000-11-09 Andrew Darrow Zymogen activation system
AU1751801A (en) * 1999-11-19 2001-05-30 Eli Lilly And Company Protein c derivatives
DE60108076T2 (de) 2000-02-02 2006-03-16 Eli Lilly And Co., Indianapolis Protein c derivate
US6630138B2 (en) 2000-02-11 2003-10-07 Eli Lilly And Company Protein C derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
WO2001089558A2 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
AU2002210388B2 (en) * 2000-10-18 2006-11-23 Perseid Therapeutics Llc Protein C or activated protein C like molecules
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
EP1453529A4 (en) 2001-09-19 2007-09-26 Oklahoma Med Res Found TREATMENT OF SEPSIS WITH TAFI
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
JP2009502118A (ja) * 2005-05-24 2009-01-29 アベスタゲン リミテッド 敗血症治療のための組み換え活性化ヒトタンパク質ｃを生成する方法
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
KR20080071116A (ko) * 2005-06-24 2008-08-01 드럭리큐어 에이피에스 기도에 영향을 미치는 염증 질환에 있어서 활성화 단백질ｃ의 기도 투여법
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
CN104262479A (zh) 2008-12-19 2015-01-07 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
EP2199387A1 (en) 2008-12-19 2010-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses for the prevention and/or the treatment of blood coagulation disorders
RU2469093C2 (ru) * 2008-12-19 2012-12-10 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
EP3811777A1 (en) * 2019-10-27 2021-04-28 Shanghai Raas Blood Products Co., Ltd. Genetically modified non-human animals humanised for protein c
WO2023171719A1 (ja) * 2022-03-08 2023-09-14 学校法人自治医科大学 活性化プロテインｃ配列

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4603105A (en) * 1982-05-27 1986-07-29 Kaplan Donald A Efficient screening methods for low probability variants
GB8327860D0 (en) * 1983-10-18 1983-11-16 Fujisawa Pharmaceutical Co Monoclonal antiprotein c antibody
US4617265A (en) * 1984-09-19 1986-10-14 Board Of Regents, University Of Texas System Colony blot assay for enterotoxigenic bacteria
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
ATE93272T1 (de) * 1985-06-27 1993-09-15 Zymogenetics Inc Expression von protein c.
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
GB8728837D0 (en) * 1987-12-10 1988-01-27 Eaton Corp Semi-automatic mechanical transmission control and control and control method
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c

Also Published As

Publication number Publication date
AR245217A1 (es) 1993-12-30
DE3885419D1 (de) 1993-12-09
PT89135A (pt) 1989-12-29
ATE96840T1 (de) 1993-11-15
AU610301B2 (en) 1991-05-16
EP0319312B1 (en) 1993-11-03
CN1035527A (zh) 1989-09-13
MX166847B (es) 1993-02-09
KR970009081B1 (en) 1997-06-05
HUT50497A (en) 1990-02-28
IE883612L (en) 1989-06-04
JP2749083B2 (ja) 1998-05-13
CA1339938C (en) 1998-07-07
KR890010199A (ko) 1989-08-07
NZ227177A (en) 1990-07-26
US4992373A (en) 1991-02-12
EP0319312A2 (en) 1989-06-07
AU2650988A (en) 1989-06-08
IE61627B1 (en) 1994-11-16
RU1830081C (ru) 1993-07-23
JPH022372A (ja) 1990-01-08
IL88559A0 (en) 1989-07-31
DK672788A (da) 1989-07-28
DE3885419T2 (de) 1994-03-31
ZA889033B (en) 1990-08-29
IL88559A (en) 1994-02-27
PT89135B (pt) 1994-04-29
DK672788D0 (da) 1988-12-02
HU209587B (en) 1994-08-29
EP0319312A3 (en) 1990-09-19

Similar Documents

Publication Publication Date Title
ES2059538T3 (es) Vectores y compuestos para expresion directa de proteina c humana activada.
ES2127831T3 (es) Unidades de expresion multicistronicas y su aplicacion.
AR058982A1 (es) Vector de expresion de la proteina bicunina y metodo para producir dicha proteina
FI920923A0 (fi) Fusionsproteiner, deras framstaellning samt anvaendning.
ES2061482T3 (es) Metodo para la identificacion de secuencias de señal secretora para sintesis de proteina extracelular en bacillus.
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
AR000610A1 (es) Un método para la expresión de un polipéptido recombinante por una célula huésped
AR009436A1 (es) UNA PROTEíNA DE FUSIoN FC-OB, UNA SECUENCIA DE ÁCIDO NUCLEICO QUE LA CODIFICA, UN VECTOR, PROCEDIMIENTO DE PREPARACIoN, COMPOSICIONES FARMACÉUTICAS Y USOS.
ATE161881T1 (de) Verwendung von promotoren von filamentösen pilzen
ES2061632T5 (es) Kluyveromyces como celula hospedante.
AR013422A1 (es) UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA
AR047345A1 (es) Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
YU31791A (sh) Vektori i jedinjenja za ekspresiju zimogenih oblika humanog proteina c
ES2062982T3 (es) Clonaje y expresion del factor de crecimiento de fibroblasto acido.
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
DK0636179T3 (da) Olielegemeproteiner som bærestoffer af höjværdi-peptider i planter
DK611386A (da) Recombinant humant fsh, fremgangsmaade til fremstilling deraf og vektorer og celler til anvendelse ved fremgangsmaaden
ES2058486T3 (es) Inmunogenos nativos y recombinantes del grupo b de eimeria tenella utiles como vacunas para las coccidiosis.
ES2101716T3 (es) Vectores y compuestos para la expresion de mutantes de glicosilacion de la proteina c humana.
FI910752A0 (fi) Dna-sekvenser, vektorer och fusionspolypeptider foer att oeka sekretionen av oenskade polypeptider ur filamenterade svampar.
AR246310A1 (es) Procedimiento para la preparacion de la cadena alfa- del receptor de la interleucina 5 humana, o partes del mismo, secuencia del adn, vector y celula hospedante.
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
ES2146193T1 (es) Proteinas del virus del arrugado de las hojas de la vid (tipo 2) y sus usos.
ES2068893T3 (es) Nuevos peptidos, su uso como inmuno-supresores y procedimientos para su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 319312

Country of ref document: ES